🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Poland / NCT07245979
Recruiting Not applicable

Supplementation With Sirtuin Activators in Women With Increased Body Weight

NCT07245979 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2025-10-08
Last updated
2026-05-22

Condition(s) studied

Obesity & Overweight

Investigational drug(s) / intervention(s)

Sirtuin activatorsPlacebo

Sirtuin activators: Sirtuin acitivators supplementation for 6 months

Placebo: Placebo supplementation for 6 months

Study summary

The goal of this clinical trial is to learn if the six-month supplementation with sirtuin activators can affect metabolism in 40-to-65-year old women with increased body weight. The main questions it aims to answer are:

Does sirtuin activators affect lipid and carbohydrate metabolism? Does sirtuin activators affect oxydative stress, immune functions and cell ageing?

Researchers will compare sirtuin activators to a placebo (a look-alike substance that contains no drug) to see if drug sirtuin activators works to improve metabolic status.

Participants will:

Take sirtuin activators or a placebo every day for 6 months. Visit the university once every 3 months for checkups and tests.

Eligibility

Sex
FEMALE
Min age
40 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * females * age: 40-65 years * overweight or obese: BMI \>25 kg/m2 Exclusion Criteria: * males * BMI \< 25 kg/m2 * sirtuin activators administration for 3 months prior to study * pregnancy or breastfeeding * recent dieting or being on calorie restricted diet * receiving pharmacotherapy to treat obesity, diabetes or hyperlipidemia * post-bariatric surgery * diabetes * cancer * chronic kidney, liver or autoimmune diseases * alcohol addiction

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Poznan University of Life Sciences Poznan Poland Recruiting

More Poznan University of Life Sciences trials in Poland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07245979 on ClinicalTrials.gov ↗ ← All trials in Poland